Form 13-F position report

ULTRAGENYX PHARMACEUTICAL IN

Reported by FRED ALGER MANAGEMENT LLC

RARE CUSIP 90400D108 Manager CIK 0000003520

Reported 411,863 shares, down 36,854 (8.2%) from the prior quarter.

Reported value -29.8%; share count -8.2% vs. the prior quarter.

Reduced
% of reported 13F value 0.04% This manager · Q4 2025
Shares 411,863 Quarter-end amount reported
Reported value $9,472,849 Fair value at quarter end
Consecutive quarters held 45 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 26239000
2021-12-31 24681000
2022-03-31 20317000
2022-06-30 15643000
2022-09-30 15145000
2022-12-31 22958368
2023-03-31 21796435
2023-06-30 30266124
2023-09-30 22775573
2023-12-31 28882132
2024-03-31 27152617
2024-06-30 22559996
2024-09-30 29791354
2024-12-31 19615768
2025-03-31 18997106
2025-06-30 15647126
2025-09-30 13497408
2025-12-31 9472849
2026-03-31 6243770
2026-06-30 4779945

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ULTRAGENYX PHARMACEUTICAL IN held by FRED ALGER MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 143,155 -154,877 (-52.0%) 0.02% $4,779,945 2026-08-14
Q1 2026 Reduced 298,032 -113,831 (-27.6%) 0.03% $6,243,770 2026-05-15
Q4 2025 Reduced 411,863 -36,854 (-8.2%) 0.04% $9,472,849 2026-02-17
Q3 2025 Added 448,717 +18,378 (4.3%) 0.05% $13,497,408 2025-11-14
Q2 2025 Reduced 430,339 -94,298 (-18.0%) 0.07% $15,647,126 2025-08-14
Q1 2025 Added 524,637 +58,372 (12.5%) 0.11% $18,997,106 2025-05-16
Q4 2024 Reduced 466,265 -70,033 (-13.1%) 0.09% $19,615,768 2025-02-14
Q3 2024 Reduced 536,298 -12,607 (-2.3%) 0.14% $29,791,354 2024-11-14
Q2 2024 Reduced 548,905 -32,646 (-5.6%) 0.11% $22,559,996 2024-08-14
Q1 2024 Reduced 581,551 -22,425 (-3.7%) 0.13% $27,152,617 2024-05-15
Q4 2023 Reduced 603,976 -34,890 (-5.5%) 0.16% $28,882,132 2024-02-14
Q3 2023 Reduced 638,866 -17,239 (-2.6%) 0.13% $22,775,573 2023-11-14
Q2 2023 Added 656,105 +112,553 (20.7%) 0.15% $30,266,124 2023-08-14
Q1 2023 Added 543,552 +48,012 (9.7%) 0.12% $21,796,435 2023-05-15
Q4 2022 Added 495,540 +129,827 (35.5%) 0.12% $22,958,368 2023-02-14
Q3 2022 Added 365,713 +103,512 (39.5%) 0.08% $15,145,000 2022-11-15
Q2 2022 Reduced 262,201 -17,572 (-6.3%) 0.07% $15,643,000 2022-08-15
Q1 2022 Reduced 279,773 -13,727 (-4.7%) 0.06% $20,317,000 2022-05-16
Q4 2021 Added 293,500 +2,577 (0.9%) 0.06% $24,681,000 2022-02-14
Q3 2021 Added 290,923 +99,491 (52.0%) 0.06% $26,239,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

357 managers reported ULTRAGENYX PHARMACEUTICAL IN for Q4 2025.

Managers reporting ULTRAGENYX PHARMACEUTICAL IN in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 10,263,815 +131,087 < 0.01% $236,067,745 48 qtrs
BlackRock Inc Added 6,631,554 +206,291 < 0.01% $152,525,742 6 qtrs
STATE STREET CORPORATION Added 4,303,046 +610,559 < 0.01% $98,970,058 48 qtrs
JPMorgan Chase & Co Reduced 3,974,030 -37,399 < 0.01% $91,402,705 48 qtrs
SANDS CAPITAL MANAGEMENT LLC Reduced 3,485,724 -284,129 0.24% $80,171,652 11 qtrs
RTW INVESTMENTS LP Reduced 3,000,139 -258,127 0.69% $69,003,197 17 qtrs
BAKER BROS ADVISORS LP Unchanged 2,772,692 0 0.37% $63,771,916 21 qtrs
FMR LLC Reduced 2,666,249 -4,617,047 < 0.01% $61,323,732 48 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 2,461,910 +516,781 < 0.01% $56,623,930 48 qtrs
CITADEL ADVISORS LLC Added 2,326,125 +1,995,172 < 0.01% $53,500,875 48 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 17, 2026
Filing type
13F-HR
Position type
Equity

Voting authority reported

Sole
269,678
Shared
0
None
142,185

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.